HTLV-II and Bacterial Infections Among Injection Drug Users
Loading...
Permanent Link
Author/Creator
Author/Creator ORCID
Date
2000-06-09
Type of Work
Department
Program
Citation of Original Publication
Safaeian, Mahboobeh; Wilson, Lucy E.; Taylor, Ellen; Thomas, David L.; Vlahov, David. HTLV-II and Bacterial Infections Among Injection Drug Users. JAIDS Journal of Acquired Immune Deficiency Syndromes 24(5):p 483-487, August 15, 2000. https://journals.lww.com/jaids/Abstract/2000/08150/Expansion_of_Rare_CD8_CD28_CD11b__T_Cells_With.12.aspx
Rights
This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.
Abstract
Objective:
To examine whether select bacterial infections are associated with HTLV-II infection among injection drug users, we conducted a nested case control study within an ongoing cohort study.
Method:
HTLV-II status was determined by enzyme-linked immunosorbent assay, immunofluorescent assay, and immunoblot. Diagnosis of bacterial pneumonia, infective endocarditis, and skin abscess was confirmed by standardized chart reviews. Three sets of cases were identified based on diagnosis of bacterial pneumonia, infective endocarditis validated by chart review, or self-reported skin abscess. Each case was matched to a minimum of 5 controls by age, HIV status, and study follow-up duration. Risk factors for each bacterial infection were analyzed separately by conditional logistic regression methods.
Results:
Prevalence of HTLV-II infection ranged from 7% to 11% in cases and controls. The bivariate association of HTLV-II and bacterial pneumonia revealed an odds ratio (OR) of 1.1 (95% confidence interval [CI], 0.6-2.0); the association of infective endocarditis and HTLV-II revealed an OR of 1.7 (95% CI, 0.7-3.9); and the association between HTLV-II and skin abscess revealed an OR of 1.3 (95% CI, 0.6-2.0). These ORs were unaltered by adjustment for other factors.
Conclusion:
Our results suggest that these three bacterial infections were not significantly associated with HTLV-II infection within a population of injection drug users. Additional associations between HTLV-II infection and disease outcomes merit further exploration.